Clinical Trials Logo

Relapsed/Refractory Lymphoma clinical trials

View clinical trials related to Relapsed/Refractory Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05713110 Recruiting - Clinical trials for Relapsed/Refractory Lymphoma

A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma

Start date: February 13, 2023
Phase: Phase 2
Study type: Interventional

A phase II clinical study of tazemetostat combined with HMPL-689 in patients with R/R lymphoma. The study includes 2 phases: dose escalation phase (phase IIa) and expansion phase (phase IIb).

NCT ID: NCT05400876 Recruiting - Clinical trials for Relapsed/Refractory Lymphoma

To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Start date: June 9, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a two-phase, open-label Phase Ib clinical trial to evaluate the safety and efficacy of TQB2618 injection combined with Penpulimab in patients with relapsed and refractory lymphoma

NCT ID: NCT05293028 Not yet recruiting - Clinical trials for Relapsed/Refractory Lymphoma

Study of F527 in Patients With Relapsed or Refractory Lymphoma

Start date: May 20, 2022
Phase: Phase 1
Study type: Interventional

This study is a non-randomized, open-label, phase I dose-finding and dose-expansion study to evaluate the safety, tolerability, antitumor efficacy, PK and immunogen of F527 in patients with relapsed or refractory lymphoma sexual characteristics.

NCT ID: NCT05271279 Terminated - Clinical trials for Advanced Solid Tumor

A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors

Start date: December 24, 2021
Phase: Early Phase 1
Study type: Interventional

This is a prospective, multi-center, open-label, single-arm, investigator-initiated clinical trial to evaluate the safety and efficacy of oncolytic virus injection (OVV-01) in combination with trained immunity NK (tiNK) cell injection (IBR900) for patients with advanced malignant tumors.

NCT ID: NCT05189093 Recruiting - Clinical trials for Relapsed/Refractory Lymphoma

Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma

Start date: December 31, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a multi-center, open, single-arm phase I/II clinical study to evaluate the recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection in Chinese patients with relapsed/refractory lymphoma .

NCT ID: NCT02259010 Completed - Clinical trials for Advanced Solid Tumors

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Start date: October 22, 2014
Phase: Phase 1
Study type: Interventional

This study will assess the effect of multi-dose administration of itraconazole on the single-dose pharmacokinetics (PK) of alisertib.

NCT ID: NCT02214147 Completed - Clinical trials for Advanced Solid Tumors

Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function

Start date: August 21, 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of moderate or severe hepatic impairment on the single-dose pharmacokinetics of alisertib in adult participants with cancer.